Introduction: Zimbabwe has for a long time satisfied measles elimination criteria according to the World Health Organization Regional Office for Africa (WHO/AFRO) measles surveillance standards. In this elimination phase laboratory based surveillance becomes critical as it gives evidence on the interruption of transmission of measles virus in the country hence the performance of the laboratory has to be monitored.
Methods: This retrospective study assesses measles laboratory performance in Zimbabwe from 2004 to 2009 by monitoring laboratory surveillance quality indicators against predefined WHO indicators.
Results: Overall, 92.20% of serum specimens arrived in the laboratory in good condition, 66.8% were received in the lab within the stipulated three days and 77% of the results were sent back to the national centers within 7 days. The laboratory passed all external proficiency tests from 2005 to 2009 with 100%. The laboratory sent 13.42% of representative sera for regional reference laboratory co-testing and the concordance of results was 98.33%. An average of 27.33% of patients with positive measles IgM had vaccination history.
Discussion: Available data shows that four out of the six WHO surveillance indicators were met by the national laboratory. The timeliness of specimen shipment to the lab needs to be improved and results should be communicated to the national centers in a timely manner. Cases with no vaccination history may be due to incompletely filled out forms or inadequate case investigation. Unvaccinated cases can accumulate over time and cause outbreaks.
Conclusion: The results of the external proficiency tests show that the laboratory is performing well, with adherence to quality requirements, as indicated by proficiency tests with the regional reference laboratory. Hence the results generated by the laboratory may be reliable for surveillance.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882865 | PMC |
http://dx.doi.org/10.11599/germs.2012.1012 | DOI Listing |
Connect Tissue Res
January 2025
Graduate School of Engineering, Kogakuin University, Hachioji, Tokyo, Japan.
Objective: This study aimed to investigate the collagen fiber structure of the subcutaneous fascia, a connective tissue layer between the skin and epimysium.
Methods: Fascia samples with varying extensibility were examined using biochemical and microscopic methods.
Results: Loose fascia, the more extensible type, displayed sparsely distributed collagen fibers, while dense fascia showed tightly packed collagen fiber bundles.
Am J Sports Med
January 2025
Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Background: The efficacy of bone marrow aspirate concentrate (BMAC) in promoting bone-tendon interface (BTI) healing without any carriers remains a subject of debate.
Purpose: To evaluate BMAC effects with different carriers on tendon regeneration in a rabbit model of chronic rotator cuff tear.
Study Design: Controlled laboratory study.
Clin Exp Allergy
January 2025
Animal Radiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
J Vet Diagn Invest
January 2025
Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA.
Equid alphaherpesvirus 4 (EqAHV4; , ; equine rhinopneumonitis virus) has seldom been associated with complications such as abortion and myeloencephalopathy, given the low tendency of this virus to induce viremia. We investigated the frequency of EqAHV4 viremia in horses with fever and respiratory signs. Case selection included all equids with EqAHV4 quantitative real-time PCR (qPCR)-positive nasal secretions (defined as EqAHV4 qPCR-positive cases) submitted to a diagnostic laboratory.
View Article and Find Full Text PDFJ Exp Clin Cancer Res
January 2025
Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a second-line treatment with curative potential for leukemia patients. However, the prognosis of allo-HSCT patients with disease relapse or graft-versus-host disease (GvHD) is poor. CD4 or CD8 conventional T (Tconv) cells are critically involved in mediating anti-leukemic immune responses to prevent relapse and detrimental GvHD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!